866-997-4948(US-Canada Toll Free)

Fallopian Tube Cancer - Pipeline Review, H1 2016

Published By :

Global Markets Direct

Published Date : Apr 2016

Category :

Cancer

No. of Pages : 643 Pages

Fallopian Tube Cancer - Pipeline Review, H1 2016

Summary

Global Markets Directs, Fallopian Tube Cancer - Pipeline Review, H1 2016, provides an overview of the Fallopian Tube Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer
- The report reviews pipeline therapeutics for Fallopian Tube Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Fallopian Tube Cancer therapeutics and enlists all their major and minor projects
- The report assesses Fallopian Tube Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Fallopian Tube Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fallopian Tube Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Fallopian Tube Cancer Overview 11
Therapeutics Development 12
Pipeline Products for Fallopian Tube Cancer - Overview 12
Pipeline Products for Fallopian Tube Cancer - Comparative Analysis 13
Fallopian Tube Cancer - Therapeutics under Development by Companies 14
Fallopian Tube Cancer - Therapeutics under Investigation by Universities/Institutes 19
Fallopian Tube Cancer - Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Fallopian Tube Cancer - Products under Development by Companies 23
Fallopian Tube Cancer - Products under Investigation by Universities/Institutes 29
Fallopian Tube Cancer - Companies Involved in Therapeutics Development 30
AbbVie Inc. 30
Acetylon Pharmaceuticals, Inc. 31
Adaptimmune Therapeutics Plc 32
Aduro BioTech, Inc. 33
Advenchen Laboratories, LLC 34
Amgen Inc. 35
Astex Pharmaceuticals, Inc. 36
AstraZeneca Plc 37
Atara Biotherapeutics, Inc. 38
Bayer AG 39
Boehringer Ingelheim GmbH 40
Boston Biomedical, Inc. 41
Caladrius Biosciences, Inc. 42
Celldex Therapeutics, Inc. 43
Celsion Corporation 44
Cerulean Pharma, Inc. 45
Clovis Oncology, Inc. 46
Corcept Therapeutics Incorporated 47
Critical Outcome Technologies Inc. 48
CTI BioPharma Corp. 49
Dr. Reddy's Laboratories Limited 50
EirGenix Inc. 51
Eli Lilly and Company 52
Exelixis, Inc. 53
F. Hoffmann-La Roche Ltd. 54
Galena Biopharma, Inc. 55
Ganymed Pharmaceuticals AG 56
Genentech, Inc. 57
Genor BioPharma Co., Ltd. 58
Glycotope GmbH 59
Gradalis Inc. 60
Ignyta, Inc. 61
Immune Design Corp. 62
ImmunoGen, Inc. 63
Immunovaccine, Inc. 64
Incyte Corporation 65
Innate Pharma S.A. 66
Johnson & Johnson 67
Juno Therapeutics Inc. 68
Karyopharm Therapeutics, Inc. 69
Kyowa Hakko Kirin Co., Ltd. 70
Lee's Pharmaceutical Holdings Limited 71
Mabion SA 72
MabVax Therapeutics Holdings, Inc. 73
MedImmune, LLC 74
Medivation, Inc. 75
Merck & Co., Inc. 76
Millennium Pharmaceuticals, Inc. 77
MolMed S.p.A. 78
Mycenax Biotech Inc. 79
Novartis AG 80
Oasmia Pharmaceutical AB 81
OBI Pharma, Inc. 82
Oncobiologics, Inc. 83
Oncolix, Inc. 84
Oncolytics Biotech Inc. 85
OncoMed Pharmaceuticals, Inc. 86
Ono Pharmaceutical Co., Ltd. 87
Oxford BioMedica Plc 88
OXiGENE, Inc. 89
Pfizer Inc. 90
Pharma Mar, S.A. 91
Pharmacyclics, Inc. 92
PsiOxus Therapeutics Limited 93
Quest PharmaTech Inc. 94
Samyang Holdings Corporation 95
Sanofi Pasteur SA 96
Shenzen SiBiono GeneTech Co., Ltd. 97
Sotio a.s. 98
Synta Pharmaceuticals Corp. 99
TapImmune Inc. 100
Tesaro, Inc. 101
TetraLogic Pharmaceuticals 102
Tyrogenex, Inc. 103
Vascular Biogenics Ltd. 104
VentiRx Pharmaceuticals, Inc. 105
Vyriad 106
Fallopian Tube Cancer - Therapeutics Assessment 107
Assessment by Monotherapy Products 107
Assessment by Target 108
Assessment by Mechanism of Action 115
Assessment by Route of Administration 120
Assessment by Molecule Type 122
Drug Profiles 124
abexinostat hydrochloride - Drug Profile 124
abiraterone acetate - Drug Profile 127
ABT-767 - Drug Profile 130
acalabrutinib - Drug Profile 131
adagloxad simolenin - Drug Profile 134
afuresertib hydrochloride - Drug Profile 136
AL-3818 - Drug Profile 139
alisertib - Drug Profile 141
anetumab ravtansine - Drug Profile 146
AZD-1775 - Drug Profile 148
AZD-2014 - Drug Profile 150
AZD-5363 - Drug Profile 153
BB-503 - Drug Profile 155
bevacizumab - Drug Profile 157
bevacizumab biosimilar - Drug Profile 164
bevacizumab biosimilar - Drug Profile 166
bevacizumab biosimilar - Drug Profile 167
bevacizumab biosimilar - Drug Profile 168
bevacizumab biosimilar - Drug Profile 169
bevacizumab biosimilar - Drug Profile 170
bevacizumab biosimilar - Drug Profile 171
birinapant - Drug Profile 172
cabozantinib s-malate - Drug Profile 175
CDX-1401 - Drug Profile 180
Cellular Immunotherapy for Oncology - Drug Profile 182
Cellular Immunotherapy for Ovarian, Peritoneal and Fallopian Tube Cancer - Drug Profile 183
Cellular Immunotherapy to Target WT1 for Oncology - Drug Profile 184
CMB-305 - Drug Profile 186
COTI-2 - Drug Profile 188
CRLX-101 - Drug Profile 191
CRS-207 - Drug Profile 194
DCVAC/OvCa - Drug Profile 197
demcizumab - Drug Profile 198
DMUC-4064A - Drug Profile 202
DPX-Survivac - Drug Profile 203
eltrapuldencel-T - Drug Profile 207
enadenotucirev - Drug Profile 210
epacadostat - Drug Profile 212
fosbretabulin tromethamine - Drug Profile 214
GALE-301 - Drug Profile 218
ganetespib - Drug Profile 220
gemogenovatucel-T - Drug Profile 224
GEN-1 - Drug Profile 226
Gene Therapy to Activate p53 for Oncology - Drug Profile 229
gimatecan - Drug Profile 231
GSK-3377794 - Drug Profile 233
guadecitabine - Drug Profile 236
IMAB-027 - Drug Profile 240
ipafricept - Drug Profile 241
JCAR-020 - Drug Profile 243
LCL-161 - Drug Profile 244
lifastuzumab vedotin - Drug Profile 246
lurbinectedin - Drug Profile 248
LV-305 - Drug Profile 252
mifepristone - Drug Profile 254
mirvetuximab soravtansine - Drug Profile 257
MK-2206 - Drug Profile 259
monalizumab - Drug Profile 262
motolimod - Drug Profile 264
NGR-hTNF - Drug Profile 266
nintedanib - Drug Profile 270
niraparib - Drug Profile 276
nivolumab - Drug Profile 278
NSC-748933 - Drug Profile 286
ofranergene obadenovec - Drug Profile 288
Oncolytic Virus to Target CD46 for Gynecological Cancers and Urinary Tract Cancer - Drug Profile 290
oregovomab - Drug Profile 291
OXB-301 - Drug Profile 293
paclitaxel - Drug Profile 296
paclitaxel - Drug Profile 298
paclitaxel poliglumex - Drug Profile 301
PankoMab-GEX - Drug Profile 305
pazopanib hydrochloride - Drug Profile 306
pelareorep - Drug Profile 312
pembrolizumab - Drug Profile 317
PF-06647263 - Drug Profile 328
PGV-001 - Drug Profile 329
prexasertib - Drug Profile 330
Prolanta - Drug Profile 332
ralimetinib mesylate - Drug Profile 334
ramucirumab - Drug Profile 336
regorafenib - Drug Profile 342
ricolinostat - Drug Profile 346
rucaparib phosphate - Drug Profile 349
selinexor - Drug Profile 352
sonidegib phosphate - Drug Profile 358
STM-434 - Drug Profile 362
taladegib - Drug Profile 363
talazoparib - Drug Profile 365
tivozanib hydrochloride - Drug Profile 368
TPIV-200 - Drug Profile 372
trabectedin - Drug Profile 374
trebananib - Drug Profile 380
tremelimumab - Drug Profile 383
Vaccine for Oncology - Drug Profile 386
varlilumab - Drug Profile 387
VCP-2292 - Drug Profile 390
veliparib - Drug Profile 391
X-82 - Drug Profile 395
Fallopian Tube Cancer - Recent Pipeline Updates 397
Fallopian Tube Cancer - Dormant Projects 624
Fallopian Tube Cancer - Dormant Projects 624
Fallopian Tube Cancer - Discontinued Products 627
Fallopian Tube Cancer - Product Development Milestones 628
Featured News & Press Releases 628
Appendix 635
Methodology 635
Coverage 635
Secondary Research 635
Primary Research 635
Expert Panel Validation 635
Contact Us 635
Disclaimer 636

List of Tables
Number of Products under Development for Fallopian Tube Cancer, H1 2016 19
Number of Products under Development for Fallopian Tube Cancer - Comparative Analysis, H1 2016 20
Number of Products under Development by Companies, H1 2016 21
Number of Products under Development by Companies, H1 2016 (Contd..1) 22
Number of Products under Development by Companies, H1 2016 (Contd..2) 23
Number of Products under Development by Companies, H1 2016 (Contd..3) 24
Number of Products under Development by Companies, H1 2016 (Contd..4) 25
Number of Products under Investigation by Universities/Institutes, H1 2016 26
Comparative Analysis by Late Stage Development, H1 2016 27
Comparative Analysis by Clinical Stage Development, H1 2016 28
Comparative Analysis by Early Stage Development, H1 2016 29
Products under Development by Companies, H1 2016 30
Products under Development by Companies, H1 2016 (Contd..1) 31
Products under Development by Companies, H1 2016 (Contd..2) 32
Products under Development by Companies, H1 2016 (Contd..3) 33
Products under Development by Companies, H1 2016 (Contd..4) 34
Products under Development by Companies, H1 2016 (Contd..5) 35
Products under Investigation by Universities/Institutes, H1 2016 36
Fallopian Tube Cancer - Pipeline by AbbVie Inc., H1 2016 37
Fallopian Tube Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 38
Fallopian Tube Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2016 39
Fallopian Tube Cancer - Pipeline by Aduro BioTech, Inc., H1 2016 40
Fallopian Tube Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016 41
Fallopian Tube Cancer - Pipeline by Amgen Inc., H1 2016 42
Fallopian Tube Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 43
Fallopian Tube Cancer - Pipeline by AstraZeneca Plc, H1 2016 44
Fallopian Tube Cancer - Pipeline by Atara Biotherapeutics, Inc., H1 2016 45
Fallopian Tube Cancer - Pipeline by Bayer AG, H1 2016 46
Fallopian Tube Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 47
Fallopian Tube Cancer - Pipeline by Boston Biomedical, Inc., H1 2016 48
Fallopian Tube Cancer - Pipeline by Caladrius Biosciences, Inc. , H1 2016 49
Fallopian Tube Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016 50
Fallopian Tube Cancer - Pipeline by Celsion Corporation, H1 2016 51
Fallopian Tube Cancer - Pipeline by Cerulean Pharma, Inc., H1 2016 52
Fallopian Tube Cancer - Pipeline by Clovis Oncology, Inc., H1 2016 53
Fallopian Tube Cancer - Pipeline by Corcept Therapeutics Incorporated, H1 2016 54
Fallopian Tube Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016 55
Fallopian Tube Cancer - Pipeline by CTI BioPharma Corp., H1 2016 56
Fallopian Tube Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 57
Fallopian Tube Cancer - Pipeline by EirGenix Inc., H1 2016 58
Fallopian Tube Cancer - Pipeline by Eli Lilly and Company, H1 2016 59
Fallopian Tube Cancer - Pipeline by Exelixis, Inc., H1 2016 60
Fallopian Tube Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 61
Fallopian Tube Cancer - Pipeline by Galena Biopharma, Inc., H1 2016 62
Fallopian Tube Cancer - Pipeline by Ganymed Pharmaceuticals AG, H1 2016 63
Fallopian Tube Cancer - Pipeline by Genentech, Inc., H1 2016 64
Fallopian Tube Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2016 65
Fallopian Tube Cancer - Pipeline by Glycotope GmbH, H1 2016 66
Fallopian Tube Cancer - Pipeline by Gradalis Inc., H1 2016 67
Fallopian Tube Cancer - Pipeline by Ignyta, Inc., H1 2016 68
Fallopian Tube Cancer - Pipeline by Immune Design Corp., H1 2016 69
Fallopian Tube Cancer - Pipeline by ImmunoGen, Inc., H1 2016 70
Fallopian Tube Cancer - Pipeline by Immunovaccine, Inc., H1 2016 71
Fallopian Tube Cancer - Pipeline by Incyte Corporation, H1 2016 72
Fallopian Tube Cancer - Pipeline by Innate Pharma S.A., H1 2016 73
Fallopian Tube Cancer - Pipeline by Johnson & Johnson, H1 2016 74
Fallopian Tube Cancer - Pipeline by Juno Therapeutics Inc., H1 2016 75
Fallopian Tube Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 76
Fallopian Tube Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 77
Fallopian Tube Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 78
Fallopian Tube Cancer - Pipeline by Mabion SA, H1 2016 79
Fallopian Tube Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2016 80
Fallopian Tube Cancer - Pipeline by MedImmune, LLC, H1 2016 81
Fallopian Tube Cancer - Pipeline by Medivation, Inc., H1 2016 82
Fallopian Tube Cancer - Pipeline by Merck & Co., Inc., H1 2016 83
Fallopian Tube Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 84
Fallopian Tube Cancer - Pipeline by MolMed S.p.A., H1 2016 85
Fallopian Tube Cancer - Pipeline by Mycenax Biotech Inc., H1 2016 86
Fallopian Tube Cancer - Pipeline by Novartis AG, H1 2016 87
Fallopian Tube Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2016 88
Fallopian Tube Cancer - Pipeline by OBI Pharma, Inc., H1 2016 89
Fallopian Tube Cancer - Pipeline by Oncobiologics, Inc., H1 2016 90
Fallopian Tube Cancer - Pipeline by Oncolix, Inc., H1 2016 91
Fallopian Tube Cancer - Pipeline by Oncolytics Biotech Inc., H1 2016 92
Fallopian Tube Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016 93
Fallopian Tube Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 94
Fallopian Tube Cancer - Pipeline by Oxford BioMedica Plc, H1 2016 95
Fallopian Tube Cancer - Pipeline by OXiGENE, Inc., H1 2016 96
Fallopian Tube Cancer - Pipeline by Pfizer Inc., H1 2016 97
Fallopian Tube Cancer - Pipeline by Pharma Mar, S.A., H1 2016 98
Fallopian Tube Cancer - Pipeline by Pharmacyclics, Inc., H1 2016 99
Fallopian Tube Cancer - Pipeline by PsiOxus Therapeutics Limited, H1 2016 100
Fallopian Tube Cancer - Pipeline by Quest PharmaTech Inc., H1 2016 101
Fallopian Tube Cancer - Pipeline by Samyang Holdings Corporation, H1 2016 102
Fallopian Tube Cancer - Pipeline by Sanofi Pasteur SA, H1 2016 103
Fallopian Tube Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H1 2016 104
Fallopian Tube Cancer - Pipeline by Sotio a.s., H1 2016 105
Fallopian Tube Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016 106
Fallopian Tube Cancer - Pipeline by TapImmune Inc., H1 2016 107
Fallopian Tube Cancer - Pipeline by Tesaro, Inc., H1 2016 108
Fallopian Tube Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2016 109
Fallopian Tube Cancer - Pipeline by Tyrogenex, Inc., H1 2016 110
Fallopian Tube Cancer - Pipeline by Vascular Biogenics Ltd., H1 2016 111
Fallopian Tube Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2016 112
Fallopian Tube Cancer - Pipeline by Vyriad, H1 2016 113
Assessment by Monotherapy Products, H1 2016 114
Number of Products by Stage and Target, H1 2016 116
Number of Products by Stage and Mechanism of Action, H1 2016 123
Number of Products by Stage and Route of Administration, H1 2016 128
Number of Products by Stage and Molecule Type, H1 2016 130
Fallopian Tube Cancer Therapeutics - Recent Pipeline Updates, H1 2016 404
Fallopian Tube Cancer - Dormant Projects, H1 2016 631
Fallopian Tube Cancer - Dormant Projects (Contd..1), H1 2016 632
Fallopian Tube Cancer - Dormant Projects (Contd..2), H1 2016 633
Fallopian Tube Cancer - Discontinued Products, H1 2016 634

List of Figures
Number of Products under Development for Fallopian Tube Cancer, H1 2016 19
Number of Products under Development for Fallopian Tube Cancer - Comparative Analysis, H1 2016 20
Number of Products under Development by Companies, H1 2016 21
Number of Products under Investigation by Universities/Institutes, H1 2016 26
Comparative Analysis by Late Stage Development, H1 2016 27
Comparative Analysis by Clinical Stage Development, H1 2016 28
Comparative Analysis by Early Stage Products, H1 2016 29
Assessment by Monotherapy Products, H1 2016 114
Number of Products by Top 10 Targets, H1 2016 115
Number of Products by Stage and Top 10 Targets, H1 2016 115
Number of Products by Top 10 Mechanism of Actions, H1 2016 122
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 122
Number of Products by Top 10 Routes of Administration, H1 2016 127
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 127
Number of Products by Molecule Types, H1 2016 129
Number of Products by Stage and Molecule Types, H1 2016 129

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *